Teva Pharmaceutical Industries (TASE: TEVA) submitted a bid on August 28, 2026, to acquire a novel neuroscience product from BioXcel Therapeutics. The asset is a dexmedetomidine sublingual film currently under FDA review for the at-home treatment of agitation associated with schizophrenia or bipolar disorders.
If approved, the product would represent the first at-home treatment option for this condition. The acquisition is being conducted through a court-supervised sale process.
The transaction remains subject to bankruptcy court approval and potential higher bids from other parties. This move aligns with Teva's strategy to acquire assets with high strategic fit and long-term value potential.